These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 37230531

  • 1. Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer.
    Berliner C, Steinhelfer L, Chantadisai M, Kroenke M, Koehler D, Pose R, Bannas P, Knipper S, Eiber M, Maurer T.
    J Nucl Med; 2023 Jul; 64(7):1036-1042. PubMed ID: 37230531
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jul; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
    Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
    [Abstract] [Full Text] [Related]

  • 4. Feasibility of 99mTc-MIP-1404 for SPECT/CT Imaging and Subsequent PSMA-Radioguided Surgery in Early Biochemically Recurrent Prostate Cancer: A Case Series of 9 Patients.
    Koehler D, Sauer M, Klutmann S, Apostolova I, Lehnert W, Budäus L, Knipper S, Maurer T.
    J Nucl Med; 2023 Jan; 64(1):59-62. PubMed ID: 35835582
    [Abstract] [Full Text] [Related]

  • 5. 99mTc-PSMA targeted robot-assisted radioguided surgery during radical prostatectomy and extended lymph node dissection of prostate cancer patients.
    Yılmaz B, Şahin S, Ergül N, Çolakoğlu Y, Baytekin HF, Sökmen D, Tuğcu V, Taşçı Aİ, Çermik TF.
    Ann Nucl Med; 2022 Jul; 36(7):597-609. PubMed ID: 35426599
    [Abstract] [Full Text] [Related]

  • 6. Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.
    Janssen JC, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR.
    Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
    [Abstract] [Full Text] [Related]

  • 7. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels.
    Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, Bäuerle T, Goebell P, Cordes M.
    Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
    [Abstract] [Full Text] [Related]

  • 8. An Australian experience using Tc-PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy.
    Duncan I, Ingold N, Martinez-Marroquin E, Paterson C.
    Prostate; 2023 Jul; 83(10):970-979. PubMed ID: 37051636
    [Abstract] [Full Text] [Related]

  • 9. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ.
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [Abstract] [Full Text] [Related]

  • 10. 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.
    Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, van Leeuwen FWB, Haller B, Horn T, Heck MM, Gschwend JE, Schwaiger M, Wester HJ, Eiber M.
    Eur Urol; 2019 Apr; 75(4):659-666. PubMed ID: 29625755
    [Abstract] [Full Text] [Related]

  • 11. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer.
    Gondoputro W, Scheltema MJ, Blazevski A, Doan P, Thompson JE, Amin A, Geboers B, Agrawal S, Siriwardana A, Van Leeuwen PJ, van Oosterom MN, Van Leeuwen FWB, Emmett L, Stricker PD.
    J Nucl Med; 2022 Nov; 63(11):1659-1664. PubMed ID: 35241483
    [Abstract] [Full Text] [Related]

  • 12. An Analysis of the Diagnostic Performance of Tc-99m PSMA SSPECT/CT in Biochemically Recurrent Prostate Cancer Compared with Ga-68 PSMA PET/CT: A Single-center, Prospective Study.
    Ora M, Saini VK, Dixit M, Singh UP, Gambhir S.
    Indian J Nucl Med; 2024 Nov; 39(3):170-176. PubMed ID: 39291065
    [Abstract] [Full Text] [Related]

  • 13. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.
    Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M.
    Clin Nucl Med; 2016 Sep; 41(9):e397-402. PubMed ID: 27276206
    [Abstract] [Full Text] [Related]

  • 14. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C, Zhu Y, Su H, Xu X, Zhang Y, Ye D, Hu S.
    Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
    [Abstract] [Full Text] [Related]

  • 15. 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
    Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Prostate; 2018 Jan; 78(1):54-63. PubMed ID: 29105797
    [Abstract] [Full Text] [Related]

  • 16. Eligibility for 177Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer.
    Cook GJR, Wong WL, Sanghera B, Mangar S, Challapalli A, Bahl A, Bassett P, Leaning D, Schmidkonz C.
    J Nucl Med; 2023 Feb; 64(2):227-231. PubMed ID: 36302657
    [Abstract] [Full Text] [Related]

  • 17. [99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center.
    Werner P, Neumann C, Eiber M, Wester HJ, Schottelius M.
    EJNMMI Res; 2020 May 07; 10(1):45. PubMed ID: 32382945
    [Abstract] [Full Text] [Related]

  • 18. Dosimetry estimation and preliminary clinical application of [99mTc]Tc-HYNIC-PSMA-XL-2 in prostate cancer.
    Yang H, Gao Z, Xu X, Liu C, Hu S, Zhang J, Song S.
    Ann Nucl Med; 2023 Jan 07; 37(1):60-69. PubMed ID: 36346503
    [Abstract] [Full Text] [Related]

  • 19. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).
    Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ.
    Eur Urol Oncol; 2021 Aug 07; 4(4):635-644. PubMed ID: 32675047
    [Abstract] [Full Text] [Related]

  • 20. The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.
    Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW.
    Ann Surg Oncol; 2019 Feb 07; 26(2):653-659. PubMed ID: 30324468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.